Provexis plc
PXS.L · London Stock Exchange · GBp
0,855GBp
0,00 (0,00 %)Stand 9. Nov., 17:15
Kennzahlen
- Eröffnung
- 0,777
- Vortag
- 0,855
- Tagesspanne
- 0,7419 – 0,9681
- 52 Wochen
- 0,555 – 1,55
- Volumen
- 31.746
- Ø Volumen
- 1,01 Mio.
- Börsenwert
- 20,06 Mio. p
- KGV
- –
- Gewinn je Aktie (TTM)
- –
- Dividendenrendite
- –
- Beta
- 0,7
- Nächste Zahlen
- –
Finanzen
Gerade nicht verfügbar.
Bewertung
Gerade nicht verfügbar.
Analysten
Einstufungen
Gerade nicht verfügbar.
Kursziel
Gerade nicht verfügbar.
Quartalszahlen
Gerade nicht verfügbar.
Dividenden und Splits
Gerade nicht verfügbar.
Aktiensplits
Gerade nicht verfügbar.
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
Gerade nicht verfügbar.
Vergleichbare Unternehmen
Gerade nicht verfügbar.
Über das Unternehmen
Operating globally, Provexis plc, along with its associated companies, specializes in the creation, licensing, and commercialization of functional foods, medical nutritional products, and dietary supplements. A key offering is Fruitflow, a unique tomato extract designed to reduce the tendency for abnormal blood clot formation, which is linked to severe cardiovascular conditions such as heart attacks and strokes. This versatile extract is available in syrup and powder formats for integration into various food and beverage items, as well as dietary supplements. The company also provides Fruitflow + Omega-3, a capsule-based supplement aimed at fostering healthy blood circulation and supporting normal cardiac function. Provexis plc holds a strategic collaboration agreement with By-Health Co., Ltd. Its products are distributed through both physical retail channels and digital online platforms. Founded in 1999, Provexis plc has its headquarters situated in Reading, United Kingdom.
- CEO
- Ian Ford
- Mitarbeitende
- 2
- Hauptsitz
- Reading, BR, GB
- Sektor
- Healthcare
- Branche
- Drug Manufacturers - Specialty & Generic
- Börsengang
- 28. Juni 2004
- Website
- provexis.com
Nachrichten
Gerade nicht verfügbar.
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.